Effect of Recombinant Human Endostatin in the Treatment of Advanced NSCLC and its Influence on Serum Level of Tumor Markers and Angio-genesis
To investigate the effect of recombinant human endostatin injection in the treatment of advanced non-small cell lung cancer(NSCLC)and its influence on serum level of tumor markers and angiogenesis,86 patients with advanced NSCLC admitted to the authour's hospital from January 2020 to June 2021 were divided into the control group(43 cases)and the treatment group(43 cases)according to the distribution principle of random number table.The control group was treated with gemcitabine hydrochloride for injec-tion+cisplatin for injection,and the treatment group was treated with recombinant human endostatin injection on the basis of the con-trol group.Both groups took 14 d as a cycle and continued treatment for 1 cycle.The curative effect after 1 cycle of treatment,pulmo-nary function index,serum level of tumor marker,angiogenesis index,quality of life and safety during treatment were compared between the two groups.Compared with the objective response rate(ORR)of the control group(46.51％),the treatment group had a higher ORR after 1 cycle of treatment(72.09％,P＜0.05).Compared with that before treatment,after 1 cycle of treatment,the forced expiratory volume in the first second(FEV1),forced vital capacity(FVC),maximum expiratory flow rate(PEF)and score of the quality of life questionnaire-lung cancer 13(QLQ-LC13)of the two groups increased,and those in the treatment group were higher than those in the control group(P＜0.05);the serum levels of human cytokeratin 21-1 fragment(CYFRA21-1),thymidine kinasei(TK-1),squamous cell carcinoma antigen(SCC-Ag),carbohydrate antigen 125(CA1 25),carcinoembryonic antigen(CEA),hypoxia inducible factor-1 α(HIF-1 α),vascular endothelial growth factor(VEGF),and the peripheral blood levels of circulating endothelial cells(aCECs),circulating endothelial cells(CECs)of the two groups decreased,and those in the treatment group were lower than those in the control group(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the control group and the treatment group during treatment(18.60％vs 13.95％,P＞0.05).Recombinant human endostatin injection could effectively regulate pulmonary function,angiogenesis indexes and serum level of tumor marker in patients with advanced NSCLC,improve pulmonary function,inhibit angiogenesis,control tumor progression,and further improve the quality of life and efficacy of patients,with higher safety.
Non small cell lung cancerAdvancedRecombinant human endostatin injectionGemcitabine hydrochloride for injec-tionCisplatin for injectionTumor markersAngiogenesisPulmonary function
NETL
NSTL
万方数据
